Sarilumab

N/A

Report date: 2026/05/23 20:00:57

Base Information

Drug NameSarilumab
Drug Alias Name萨瑞鲁单抗Sarilumabum沙立芦人单抗KevzaraSAR-153191 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-6 receptor alpha subunit antagonistsInterleukin-6 receptor subunit beta antagonists
TargetsInterleukin-6 receptor alpha subunitInterleukin-6 receptor subunit beta
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Polyarticular Juvenile Idiopathic ArthritisSarcoidosis +[10] 
Global Approved IndicationsArthritis, Rheumatoid
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/05/22
Country/TerritoryCzechiaBelgiumCanada +[50] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSanofiRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesStanford UniversitySanofiSanofi-Synthelabo +[6] 
Inactive CompaniesAsst Fatebenefratelli SaccoMaimonides Biomedical Research Institute Of CordobaUniversity Of Navarra +[4] 
Active IndicationsPolyarticular Juvenile Idiopathic ArthritisSarcoidosisPolymyalgia Rheumatica +[6] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)UveitisSpondylitis, Ankylosing +[4] 

Other Information

ATC CodeL04AC14
Related LinksWikipediaDrugBankKEGG